The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1018
ISSUE1018
January 16, 1998
Cerivastatin for Hypercholesterolemia
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Cerivastatin for Hypercholesterolemia
January 16, 1998 (Issue: 1018)
Cerivastatin (Baycol - Bayer), a new HMG-CoA reductase inhibitor (or "statin"), has been approved by the FDA for treatment of hypercholesterolemia. Cerivastatin is the sodium salt of a synthetic fluorophenyl pyridinyl-substituted heptanoic...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.